Skip to main content

Table 3 Follow-up on patients at 2 years clinical outcomes

From: Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study

Clinical outcomes (n, %)

DM

No-DM

G2‑DES

N = 1862

BP‑DES

N = 421

p

G2‑DES

N = 4232

BP‑DES

N = 1151

P

MACE

219 (11.8)

60 (14.3)

0.159

403 (9.5)

129 (11.2)

0.089

 All-cause death

27 (1.5)

6 (1.4)

0.969

40 (0.9)

16 (1.4)

0.187

 Cardiac death

16 (0.9)

2 (0.5)

0.554

25 (0.6)

6 (0.5)

0.782

 Non-fatal MI

37 (2.0)

15 (3.6)

0.050

75 (1.8)

17 (1.5)

0.493

 ST

20 (1.1)

5 (1.2)

0.797

32 (0.8)

6 (0.5)

0.399

Revascularization

145 (7.8)

39 (9.3)

0.315

279 (6.6)

89 (7.7)

0.174

 TVR

81 (4.4)

24 (5.7)

0.232

136 (3.2)

59 (5.1)

0.002

 TLR

66 (3.5)

22 (5.2)

0.106

92 (2.2)

52 (4.5)

< 0.001

 Stroke

26 (1.4)

4 (1.0)

0.468

51 (1.2)

15 (1.3)

0.789

Bleeding

124 (6.7)

21 (5.0)

0.204

310 (7.3)

79 (6.9)

0.592

 BARC 2_5

50 (2.7)

8 (1.9)

0.355

123 (2.9)

31 (2.7)

0.701

 BARC 3_5

8 (0.4)

1 (0.2)

> 0.999

24 (0.6)

4 (0.3)

0.358

  1. DM diabetes mellitus, G2-DES second generation drug-eluting stent, BP-DES biodegradable polymer drug-eluting stent, MACE major adverse cardiac events, MI myocardial infarction, ST stent thrombosis, TVR target vessel revascularization, TLR target lesion revascularization, BARC Bleeding Academic Research Consortium definition